Author | Bhatt, N. B. | |
Author | Barau, C. | |
Author | Amin, A. | |
Author | Baudin, E. | |
Author | Meggi, B., | |
Author | Silva, C | |
Author | Furlan, V. | |
Author | Grinsztejn, Beatriz | |
Author | Barrail-Tran, A. | |
Author | Bonnet, M. | |
Author | Taburet, A. M. | |
Author | ANRS 12146-CARINEMO Study Group | |
Access date | 2019-08-29T12:05:53Z | |
Available date | 2019-08-29T12:05:53Z | |
Document date | 2014 | |
Citation | BHATT, N. B. et al. Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment. Antimicrobial Agents and Chemotherapy, v. 58, n. 6, p. 3182-3190, 2014. | pt_BR |
ISSN | 0066-4804 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/35177 | |
Language | eng | pt_BR |
Publisher | American Society for Microbiology | pt_BR |
Rights | open access | pt_BR |
Title | Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment | pt_BR |
Type | Article | pt_BR |
DOI | 10.1128/AAC.02379-13 | |
Abstract | This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique. Thirty-eight patients on antituberculosis therapy based on rifampin and isoniazid participated in the substudy (57.9% males; median age, 33 years; median weight, 51.9
kg; median CD4 T cell count, 104 cells/l; median HIV-1 RNA load, 5.5 log copies/ml). The daily doses of rifampin and isoniazid were 10 and 5 mg/kg of body weight, respectively. Twenty-one patients received 200 mg of nevirapine twice a day (b.i.d.), and 17 patients received 600 mg of efavirenz once a day (q.d.) in combination with lamivudine and stavudine from day 1 until the end of the study. Blood samples were collected at regular time-dosing intervals after morning administration of a fixed-dose combination of rifampin and isoniazid. When rifampin was administered alone, the median maximum concentration of drug in serum (Cmax) and the area under the concentration-time curve (AUC) at steady state were 6.59 mg/liter (range, 2.70 to 14.07 mg/
liter) and 27.69 mg · h/liter (range, 11.41 to 109.75 mg · h/liter), respectively. Concentrations remained unchanged when rifampin was coadministered with nevirapine or efavirenz. When isoniazid was administered alone, the median isoniazid Cmax and AUC at steady state were 5.08 mg/liter (range, 1.26 to 11.51 mg/liter) and 20.92 mg · h/liter (range, 7.73 to 56.95 mg · h/liter), respectively. Concentrations remained unchanged when isoniazid was coadministered with nevirapine; however, a 29% decrease in the isoniazid AUC was observed when isoniazid was combined with efavirenz. The pharmacokinetic parameters of rifampin and isoniazid when coadministered with nevirapine or efavirenz were not altered to a clinically significant extent in these severely immunosuppressed HIV-infected patients. Patients experienced favorable clinical outcomes. | pt_BR |
Affilliation | Ministério da Saúde. Instituto Nacional de Saúde. Maputo, Mozambique / Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France. | pt_BR |
Affilliation | Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France. | pt_BR |
Affilliation | Epicentre. Paris, France. | pt_BR |
Affilliation | Ministério da Saúde. Instituto Nacional de Saúde. Maputo, Mozambique. | pt_BR |
Affilliation | Epicentre. Paris, France. | pt_BR |
Affilliation | Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France / University Paris Sud. Faculty of Pharmacy. Paris, France. | pt_BR |
Affilliation | Epicentre. Paris, France. | pt_BR |
Affilliation | Assistance Publique Hôpitaux de Paris. Assistance Publique Hôpitaux de Paris. Bicêtre Hospital. Clinical Pharmacy, Paris, France. | pt_BR |
Subject | HIV-tuberculosis coinfection | pt_BR |
Subject | Antiretroviral treatment | pt_BR |
Subject | Rifampin | pt_BR |
Subject | Isoniazid | pt_BR |
Subject | Nevirapine | pt_BR |
Subject | Efavirenz | pt_BR |
e-ISSN | 1098-6596 | |
Embargo date | 2020-08-29 | |